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ABSTRACT
Despite multimodal therapies, a high percentage of high-risk neuroblastoma (NB) 
become refractory to current treatments, most of which interfere with cell cycle and 
DNA synthesis or function, activating the DNA damage response (DDR). In cancer, 
this process is frequently altered by deregulated expression or function of several 
genes which contribute to multidrug resistance (MDR). MicroRNAs are outstanding 
candidates for therapy since a single microRNA can modulate the expression of 
multiple genes of the same or different pathways, thus hindering the development 
of resistance mechanisms by the tumor. We found several genes implicated in the 
MDR to be overexpressed in high-risk NB which could be targeted by microRNAs 
simultaneously. Our functional screening identified several of those microRNAs 
that reduced proliferation of chemoresistant NB cell lines, the best of which was 
miR-497. Low expression of miR-497 correlated with poor patient outcome. The 
overexpression of miR-497 reduced the proliferation of multiple chemoresistant NB 
cell lines and induced apoptosis in MYCN-amplified cell lines. Moreover, the conditional 
expression of miR-497 in NB xenografts reduced tumor growth and inhibited vascular 
permeabilization. MiR-497 targets multiple genes related to the DDR, cell cycle, 
survival and angiogenesis, which renders this molecule a promising candidate for 
NB therapy.
INTRODUCTION
Neuroblastoma (NB) is an extracranial neoplasm 
originating in the neural crest lineage of the sympathetic 
nervous system. It is considered an embryonal cancer [1] and 
occurs mainly in children between 0 and 4 years of age. NB 
has an incidence in Europe and North-America of 10.5 cases 
per million in children and adolescents and accounts for 
12 to 15% of all cancer-related deaths in children [2, 3]. 
NB patients are assigned to three different risk categories 
according to clinicopathologic variables such as age at 
diagnosis, MYCN oncogene amplification, tumor histology 
and DNA ploidy. Overall survival for low-risk patients 
is excellent; minimal intervention is required and, on 
occasions, surgery alone suffices. Intermediate-risk patients 
generally have good prognosis and are treated with surgery 
and standard chemotherapy. However, high-risk patients 
have poor prognosis and need intense chemotherapeutic 
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regimens. Despite the aggressive treatment, 50–60% of 
these patients will not achieve long-term cure owing to 
disease progression and resistance to current therapies [4–7]. 
Acquired drug resistance is often characterized by multiple 
drug resistance (MDR), which is defined as insensitivity of 
cancer cells to cytotoxic and cytostatic action of a number 
of structurally and functionally unrelated chemotherapeutic 
agents [8]. In general, this MDR is a major obstacle to the 
success of chemotherapy. Some key elements have been 
shown to participate in the MDR process in NB, and include 
the increased expression of oncogenes such as MYCN, 
TrkB/BDNF signaling, or alterations in the DNA damage 
response (DDR) elements such as p53 [9–12], CHEK1 [13] 
or PLK1 [14, 15], among others. It has also been 
demonstrated that major elements of the apoptotic 
signaling cascade, including BCL2 family members, 
survivin and caspase-8 present abnormal expression or 
activation patterns [16, 17]. In addition, acquired resistance 
to chemotherapeutic agents may be produced by enhanced 
drug efflux due to overexpression of membrane transporters 
[18, 19]. 
Owing to the multiple mechanisms that lead to 
NB resistance to therapy, targeting single elements of a 
pathway may not suffice. In this respect, it is desirable 
to find molecules, such as microRNAs, that can regulate 
multiple cellular processes, thereby minimizing the 
risk of resistance and improving the clinical response. 
MicroRNAs (miRNAs) are endogenous small non-coding 
RNAs that regulate gene expression by direct binding 
to the 3′untranslated (UTR) region of mRNAs, blocking 
their translation and/or inducing their degradation [20]. 
MiRNAs are upstream regulators that can simultaneously 
target large numbers of protein-coding genes and multiple 
cancer pathways. Emerging cumulative data reveal 
functional roles of miRNAs in the origin and progression 
of NB [21]. Recently, an overall reduction in miRNAs was 
observed in advanced NB, mainly due to alterations in the 
miRNA processing machinery [22]. Therefore, miRNA(s) 
restoration represents an attractive novel therapeutic 
approach against aggressive tumors that do not respond to 
conventional chemotherapies. 
In order to select the best miRNA candidates, we 
sought to analyze the expression levels of the MDR-
related genes in human NB samples and select those that 
were highly expressed in the most aggressive NBs (Stage 4, 
MYCN-amplified tumors). 3′UTR analysis of those 
genes revealed that most of them contain binding sites for 
various miRNAs in their sequence. Those miRNAs that 
were capable of targeting 3 or more MDR-altered genes 
simultaneously were then selected for functional analysis 
in cellular and animal models of chemoresistant NB. 
Our strategy permitted the identification of miR-497, the 
restoration of which impairs cellular proliferation in vitro 
and in vivo. MiR-497 can be a new therapeutic tool for NB 
therapy due to its ability to target multiple genes related to 
cell cycle, cell survival, and angiogenesis regulators.
RESULTS
Several DNA-damage response and 
detoxification-associated genes are overexpressed 
in advanced neuroblastoma
The expression of the most important MDR-
associated genes (DDR mediators and pumps and 
detoxification genes) was analyzed in different stages 
of human NB tumors [23] and whether they could be 
simultaneously targeted by miRNAs was explored 
(Figure 1A). Twenty-three out of forty-five genes were 
found to be overexpressed in the worst prognosis NB group 
(Stage 4, MYCN amplified) (Supplementary Table 1). 
Analysis of the 3′UTR of the overexpressed genes 
showed almost all of them to being susceptible to be 
regulated by miRNAs. Twenty-eight different miRNAs 
were found to be potential regulators of at least 3 
different analyzed genes (Supplementary Table 2) 
by at least two independent miRNA-binding site 
prediction algorithms (i.e. TargetScan [24], PicTar [25] 
and miRANDA [26]).
The miR-15 family member miR-497 has the 
highest therapeutic potential
The effects of miRNA expression listed in 
Supplementary Table 2 were evaluated in two different 
NB cell lines derived from tumors resistant to currently-
used chemotherapeutic drugs (i.e. cisplatin, etoposide, 
melphalan) at clinically-achievable doses in children [27]. 
MiRNAs were reverse-transfected into CHLA-90 and SK-
N-BE(2) NB cell lines and proliferation was evaluated 
at 96 h post-transfection. Figure 1B shows that 4 of 28 
miRNAs (miR-185, miR-101, miR-34a and miR-497) 
did significantly reduce the number of cells of both cell 
lines compared to MOCK-transfected cells or versus non-
targeting miRNA (miR-Control), with miR-497 being the 
miRNA with the clearest effects in both NB cell lines. 
MiR-497 belongs to the miR-15 family which 
has five additional members (miR-15a, miR-15b, 
miR-16-1/2, miR-195 and miR-424); all share the 
same seed region, and thereby potentially regulate 
a similar pool of targets (Supplementary Table 3). 
When the expression of the miR-15 family 
members was analyzed in human NB tissues 
(n = 328), the low expression of miR-15a, miR-195, miR-
497 and miR-424 correlated with worse progression-free 
survival (Figure 2A). Tumors from patients with MYCN 
amplification (poor outcome) also showed reduced levels 
of miR-195, miR-497 and miR-424 (Supplementary 
Figure 1). These data suggest that replacement of miR-15 
family members could be exploited therapeutically. In 
order to clarify whether the diverse family members 
could have different therapeutic potential, we compared 
the effects of transfecting all 6 individual miRNAs on the 
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proliferation of NB cells. MiR-497 was the miR-15 family 
member which reduced the number of viable NB cells the 
most (Figure 2B). 
MiR-497 reduces proliferation of chemoresistant 
NB cells and induces apoptosis in MYCN-
amplified cell lines
The effects of miR-497 were then analyzed in 
a panel of NB cell lines representative of the major 
subclasses of NB (MYCN-amplified and non-amplified) 
over a time-course period. A reduction in cell proliferation 
started to be visible in all cell lines at 72 h post-
transfection (Figure 3A).
To further ascertain whether the effects of miR-497 
were due to a reduction in cell proliferation and/or 
increased cell death, the induction of apoptosis was 
analyzed in miR-497-transfected cells. The number of 
cells with condensed or fragmented chromatin (one of the 
hallmarks of apoptotic cell death) was found to be increased 
upon miR-497 transfection in MYCN-amplified (SK-
N-BE(2) and LA1-5s) but not in MYCN-non amplified 
cell lines (CHLA-90 and SK-N-AS) (Figure 3B–3C). 
Furthermore, the implication of caspases in miR-497-
Figure 1: Functional screening of selected miRNAs. (A) Diagram of in silico analysis carried out to select miRNAs candidates. 
(B) Twenty-eight different mimic miRNAs oligonucleotides were reverse-transfected in the chemoresistant NB cell lines CHLA-90 (MYCN 
non-amplified, gray bars) and SK-N-BE(2) (MYCN amplified, black bars). Cells were fixed and stained with crystal violet 96 h post-
transfection. Absorbance was measured at 590 nm after dissolving the crystals with 15% acetic acid. Proliferation values were normalized 
versus MOCK-transfected cells. Data represent mean ± SEM of three independent experiments (six replicates each experiment). Statistical 
significance was determined by two-tailed unpaired Student’s t-test comparing each miRNA versus miR-Control. P-values for the CHLA-
90 cell line are miR-185: 0.00012, miR-101: 4.55 × 10−05, miR-34a: 0.00028 and miR-497: 4.13 × 10−07. P-values for the SK-N-BE(2) cell 
line are miR-185: 5.05 × 10−06, miR-101: 0.00311, miR-34a: 5.17 × 10−10 and miR-497: 0.00105.
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Figure 2: MiR-15 family members expression correlates with NB prognosis and regulates cell proliferation. (A) Kaplan-
Meier progression-free survival analysis of miR-15 family members in human NB tissues (n = 328). (B) The miR-15 family members 
(miR-15a, miR-15b, miR-16-1/2, miR-195, miR-497 and miR-424) were reverse-transfected in SK-N-BE(2) and LA1-5s cells. 96 h later, 
cells were fixed and stained with crystal violet. Proliferation values were normalized versus MOCK-transfected cells. Data represent mean 
± SEM of three independent experiments (six replicates per experiment). **p < 0.01; ***p < 0.001.
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induced cell death was confirmed with a caspase activity 
assay (Figure 3D) and the cleavage of caspase-3/7 
substrate PARP (Figure 3E).
In summary, our results show that the sole ectopic 
expression of miR-497 suffices to reduce the proliferation 
of all tested chemoresistant NB cell lines and induce cell 
death in MYCN-amplified NB cells.
MiR-497 overexpression reduces tumor growth 
and vascular permeability
Since our data pointed to a therapeutic potential of 
miR-497 against refractory NB, we proceeded to engineer 
an inducible miR-497 expression system to evaluate the 
effects of miR-497 expression in vivo. The precursor 
form of miR-497 (pre-miR-497, accession # MI0003138) 
was cloned into the Tet-On lentiviral inducible vector 
(pTRIPZ, Thermo) which provides inducible expression 
of the miRNA in the presence of doxycycline. SK-N-
BE(2) cells were transduced with either pTRIPZ-Control 
or pTRIPZ-miR-497 and stable cells were selected with 
puromycin. The addition of different concentrations 
of doxycycline (0.1–1 µg/ml) to the culture media of 
pTRIPZ-miR-497-transduced cells induced miR-497 
overexpression, obtaining the highest overexpression at 
0.5 µg/ml (~40-fold) (Supplementary Figure 2A). The 
miR-497-expressing cells can be monitored by following 
the red fluorescent protein (Supplementary Figure 2B). 
The functional consequences of miR-497 overexpression 
were evaluated in proliferation and colony-formation 
assays. Concurring with our previous observations, the 
doxycycline-mediated induction of miR-497 dramatically 
reduced the proliferation and colony-formation capability 
of SK-N-BE(2) cells while doxycycline itself did not have 
any effect (Figure 4A–4C). These results were confirmed 
in the MYCN-amplified cell line LA1-5s (Supplementary 
Figure 3).
Next, we established NB tumors by the 
subcutaneous injection of 5 × 106 SK-N-BE(2) cells 
previously transduced with the pTRIPZ-miR-497 vector, 
into the right flank of NMRI-nude mice (Figure 4D). 
Once tumors were detected (day 4–5 post-injection), 
mice were randomized into two groups; while the control 
group received vehicle (2% sucrose), the miR-497 group 
received 1mg/ml doxycycline and 2% sucrose in drinking 
water ad libitum. Tumor volume was monitored every 
2–3 days over a three-week period. The overexpression of 
miR-497 in the presence of doxycycline showed a ~2–3 
fold reduction in tumor growth (day 20–22) (Figure 4E) 
and tumor weight (Figure 4F) compared to doxycycline-
untreated mice. PCR analysis confirmed the activation 
of miR-497 expression by doxycycline (Supplementary 
Figure 2C). 
During the course of the experiment, the majority 
of mice bearing NB xenografts without doxycycline 
displayed hemorrhagic tumors whereas none of the tumors 
in the doxycycline-treated arm did so (Figure 5A), 
possibly indicating specific effects of miR-497 expression 
in the tumor vasculature. This effect was further visible 
when tumors were dissected (Figure 5B). Histologic 
analysis revealed extensive hemorrhagic areas in the 
control group (Figure 5C) and few red blood cells in 
the parenchyma of miR-497-overexpressing tumors. 
The presence of red blood cells not exclusively inside 
or in the proximity of blood vessels results from high 
permeability of tumor blood vessels, a common trait of 
human NB. Additionally, the number and area of blood 
vessels were measured. Although a trend was observed 
towards a reduction in blood vessel area in miR-497-
overexpressing tumors, differences did not reach 
statistical significance (Figure 5D).
In summary, the overexpression of miR-497 in vivo 
resulted in reduced tumor growth and less permeability of 
blood vessels.
MiR-497 targets several cell cycle, survival and 
angiogenesis genes
The miR-15 family members were initially selected 
in this study owing to their potential for targeting several 
chemoresistance-associated genes such as CHEK1, 
CDC25A, WEE1 and ABCC5. We proceeded to verify 
whether these genes were truly modulated by miR-497 
overexpression in the neuroblastoma context. We decided to 
include other potential targets in the analysis that could also 
be related to the observed phenotype such as BCL2, AKT3 
and VEGFA. The transient overexpression of miR-497 
in SK-N-BE(2) and LA1-5s (MYCN amplified) cell lines 
(Figure 6A–6B, right panels) proved to cause a reduction 
in the mRNA levels of WEE1, CHEK1, BCL2, CDC25A 
and VEGFA while a reduction in ABCC5 and AKT3 was 
observed only in LA1-5s cells 48 h post-transfection 
(Figure 6A–6B, left panels). To further confirm whether 
the reduction in mRNA was followed by a decrease in 
protein levels, a Western blot was performed at different 
time-points post-miR-497 transfection. The protein levels 
of WEE1, CHEK1, BCL2 and AKT3 were reduced as early 
as 48 h upon miR-497 transfection. VEGFA reduction 
was much more evident in LA1-5s than in SK-N-BE(2), 
perhaps due to different protein stability among cell lines. 
By contrast, the levels of CDC25A remained unaltered in 
both cell lines (Figure 6C–6D).
Since WEE1 and BCL2 have been reported to be 
direct miR-497 targets in NB cells [28, 29], we proceeded 
to analyze whether the remaining candidate genes 
were also directly modulated by miR-497. CHEK1-, 
AKT3- and VEGFA- 3′UTR luciferase-reporter vectors were 
engineered and co-transfected with miR-497 or control 
mimic oligonucleotides (Figure 7). Significant reduction in 
luciferase activity was observed upon miR-497 transfection 
for CHEK1, AKT3 and VEGFA 3’UTR vectors, thereby 
indicating a direct modulation of these genes by miR-497.
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Figure 3: MiR-497 overexpression reduces proliferation of chemoresistant NB cells and induces apoptosis in MYCN-
amplified NB cells. (A) Proliferation time course comparing miR-497 versus miR-Control (25 nM) reverse transfected in CHLA-90 
and SK-N-AS cells (both non-MYCN amplified) or SK-N-BE(2) and LA1-5s cells (both MYCN amplified). (B) Representative images of 
nuclear morphology assessment at 96 h post-transfection with Hoechst staining in miR-Control and miR-497 (25 nM) reverse transfected 
NB cell lines. Arrowheads point at condensed or fragmented nuclei. (C) Quantification of apoptosis was performed from 4 representative 
images of 3 replicates per condition. (D) Caspase-3/7 activity assays and (E) representative Western blot of PARP protein at 72 h post-
transfection. SK-N-BE(2) and LA1-5s cells were reverse transfected with 25 nM of miR-Control or miR-497. Data represent mean ± 
SEM of three independent experiments *, ** or *** indicated significant differences comparing miR-497 versus miR-Control at p < 0.05, 
p < 0.01 or p < 0.001, respectively.
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Figure 4: Inducible expression of miR-497 impairs colony formation and proliferation in vitro and tumor growth in 
vivo. (A) Representative images of a colony-formation assay in pTRIPZ-Control or pTRIPZ-miR-497 stable SK-N-BE(2) cells treated 
with or without doxycycline (0.5 µg/mL) and allowed to grow for 13 days (n = 3). Expression of the TurboRFP permits the visual marking 
of miRNA-expressing cells. (B) Colonies were stained with crystal violet, photographed and the number of colonies was quantified. 
(C) Proliferation time course comparing pTRIPZ-Control or pTRIPZ-miR-497 stable SK-N-BE(2) cells with or without 0.5 µg/mL of 
doxycycline. Data represent mean ± SEM of three independent experiments (3 replicates per condition for each experiment). ** or *** 
indicated significant difference comparing cells with or without doxycycline at p < 0.01 or p < 0.001, respectively. (D) Mouse model design. 
5 · 106 of SK-N-BE(2) stably transduced cells with pTRIPZ-miR-497 (n = 20) were injected into the right flank of NMRI-nude mice. Once 
tumors were detected, mice were randomized in two groups (n = 10/group). MiR-497 expression was then induced with the administration 
of 1 mg/mL doxycycline with 2% sucrose in drinking water ad libitum. Tumor measurements were taken every 2–3 days for three weeks. 
Tumor growth (E) and weight (F) of NB xenografts derived from SK-N-BE(2)-pTRIPZ-miR497 cells. * means p < 0.05.
Oncotarget9278www.impactjournals.com/oncotarget
Collectively, these data suggest that miR-497 
may regulate proliferation, survival and tumor vascular 
permeability by targeting key genes involved in DDR 
such as WEE1 and CHEK1, cell growth and viability such 
as AKT3 and BCL2 and angiogenesis regulators such as 
VEGFA.
DISCUSSION
Resistance to current chemo- and radiotherapy 
treatments remains the main cause of cancer treatment 
failure. Most of these treatments are aimed at targeting 
the most-dividing cells interfering in the cell proliferation 
and division processes, thereby inducing DNA damage 
and, consequently, activating the DNA-damage response 
(DDR). The alteration of this process contributes notably 
to the multi-drug resistance phenotype and consists of a 
well-orchestrated signaling cascade which halts cell cycle 
progression and repairs DNA. When DNA damage is 
beyond repair, cell death mechanisms are triggered. Genetic 
and/or epigenetic alterations of this complex network, 
may predispose to cancer, promote tumor progression or 
participate in the resistance to current therapies [30]. 
Outcomes for low- and intermediate-risk NB 
patients are excellent, but survival for high-risk NB is 
less than 50%. High-risk NB may be initially responsive 
Figure 5: Overexpression of miR-497 in vivo reduces permeability of blood vessels. (A) Representative images of mice bearing 
NB xenografts with and without doxycycline treatment and quantification of mice with hemorrhagic tumors. (B) Representative images of 
dissected tumors (bar indicates 1 cm). (C) Hemorrhagic area was determined developing endogenous tissue peroxidase (mostly from red 
blood cells) using DAB precipitate deposition. Representative histology images of dissected tumors and quantification of hemorrhage areas 
of the images. (D) Vascularization was determined using an anti-CD31 (PECAM1) antibody and Envision anti-Rabbit HRP-conjugated 
secondary antibody complex. Representative histology images of dissected tumors and quantification of vascular areas of the images. 
Quantification of both vascularization and hemorrhaging was made from 3 representative images of 4 independent tumors per group.
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to DNA-damaging therapies; however, most patients 
will relapse and be refractory to conventional therapies, 
rendering NB a paradigm of chemoresistant tumors [31]. 
The implication of several DDR elements in the resistance 
of NB to therapy has been proposed, with TP53 [32–34], 
antiapoptotic Bcl-2 family members such as Bcl-2 [35] 
or Bcl-XL [36], and checkpoint regulators [37], being the 
most characterized. Therefore, targeting different DDR 
components simultaneously may improve the clinical 
response of high-risk patients. 
MiRNAs are small non-coding RNAs that regulate 
gene expression generally by direct binding to the 3′UTR 
of their target genes. One of the features that renders 
miRNAs striking candidates for therapy is that a single 
miRNA can modulate the expression of multiple genes 
of the same or different pathways, thus hindering the 
development of resistance mechanisms by the tumor.
We propose the use of miRNAs as a new clinical 
tool to treat advanced NB that do not respond to current 
chemotherapies. We screen the therapeutic potential of 
Figure 6: MiR-497 regulates the expression of cell cycle, survival and angiogenesis genes. (A) SK-N-BE(2) and (B) LA1-5s 
cells were transfected with 25 nM of miR-Control or miR-497 oligonucleotides in triplicate. The expression of the indicated genes (left 
panels) and miR-497 (right panels) was determined by qRT-PCR at 48 h post-transfection. *p < 0.05 ; **p < 0.01 and ***p < 0.001. 
Representative Western blot of the indicated proteins at 48 to 96 h post-transfection in (C) SK-N-BE(2) and (D) LA1-5s cells. Arrowheads 
point at the specific band.
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miRNAs that could simultaneously target several MDR-
related genes that are overexpressed in advanced NB 
(stage 4 with MYCN amplification). We identified 
miR-497 as the most anti-proliferative miRNA in two 
representative NB cell lines resistant to currently-used 
chemotherapeutic drugs. Low miR-497 expression was 
associated with shorter event-free survival and MYCN 
amplification in our cohort of human NB samples, 
suggesting a tumor-suppressor role. In accordance 
with our findings, miR-497 has also been found to be 
underexpressed in advanced stages of cancer or when 
tumor samples were compared with normal counterpart 
tissues, and play a tumor-suppressor role in other 
malignancies such as peritoneal [38], adrenocortical [39], 
prostate [40] and hepatocellular carcinomas [41, 42]; 
malignant astrocytoma [43]; neuroblastoma [29]; gastric 
[44, 45], cervical [46], bladder [47], pancreatic [48], 
ovarian [49], colorectal [50], non-small cell lung cancer 
[51], and male [52] and female breast cancer [53–56].
The overexpression of miR-497 reduced the 
proliferation of all cell lines analyzed and induced 
apoptosis in MYCN-amplified cell lines. Additionally, 
we provide the first evidence of antitumoral activity of 
miR-497 in a preclinical mouse model of pediatric cancer. 
Figure 7: CHEK1, AKT3 and VEGFA are miR-497 direct targets. HEK-293T cells were co-transfected with 50 ng/well of 
indicated luciferase-reporter vector and 25 nM of miR-497 or miR-Control. 24 h post-transfection Luciferase Assay for (A) CHEK1, 
(B) AKT3 or (C) VEGFA constructs was performed. Data represent mean ± SEM of three independent experiments (six replicates per 
experiment). ***p < 0.001. Right panels show the miR-497-binding site sequence within the indicated human genes. Seeding region is 
highlighted in blue.
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Concurring with our results, in the majority of cellular 
models studied, the restoration of miR-497 levels impaired 
cell cycle progression and/or induced apoptosis in vitro 
and reduced tumor growth in vivo [45, 51, 57, 58]. Among 
miR-497 targets, multiple cell cycle regulators such as 
CCNE1, CDC25A, CCND3, CDK4 [41] or proteins 
involved in apoptosis such as BCL2 [44], BCL-w [54] and 
BIRC5 [47] have been described. In NB, only the WEE1 
G2 checkpoint kinase has been recently identified [29]. 
We observed a downregulation of cell cycle 
regulators (CHEK1 and WEE1), cell survival proteins 
(AKT3 and BCL2) and the vascular permeability factor 
(VEGFA) after miR-497 overexpression and all have been 
identified as direct miR-497 targets. 
One of the targets most affected by the ectopic 
expression of miR-497 was CHEK1. This cell cycle 
regulator was also found to be a plausible therapeutic 
target in NB by RNAi screening of several protein kinases 
[13]. We found CHEK1 to be highly expressed in advanced 
NB stages, with higher levels in MYCN-amplified tumors 
and a clear correlation between high CHEK1 mRNA 
levels and shorter progression-free and overall survival 
(Supplementary Figure 4A–4D). An inverse correlation 
was observed between the mRNA levels of CHEK1 
and miR-497 in human NB tumors (Supplementary 
Figure 4E). Interestingly, simultaneous pharmacologic 
inhibition of CHEK1 and WEE1, both miR-497 targets, 
acted synergistically to impair neuroblastoma cell growth 
in vitro and in vivo [59], further demonstrating the 
therapeutic potential of miR-497.
AKT is the central component of the PI3K/AKT/
mTOR pathway which is often hyperactivated in NB 
tumors [60]. This kinase is able to phosphorylate and 
regulates the function of a plethora of substrates that 
are critical for growth, proliferation, survival and 
angiogenesis, among other cellular processes [61]. There 
are three AKT isoforms which may play different roles 
in human cancer [62]. Particularly, AKT3 is abundantly 
expressed in the nervous system and has been associated 
with the development of neural crest-derived tumors 
such as melanoma [63] or involved the progression of 
gliomas through activation of the DNA repair pathway 
[64]. Interestingly, AKT3 has been shown to modulate 
angiogenesis through the control of VEGFA expression 
[65], another of our miR-497-identified targets. Therefore, 
the downregulation of AKT3 and VEGFA, both of the 
same axis, may ensure a reduction in the production 
and secretion of VEGFA. In our established xenografts, 
the inducible expression of miR-497 was able to reduce 
tumor growth and the permeability of blood vessels. 
This latter effect could be particularly relevant for cancer 
therapy. A disorganized and leaky blood vessel network is 
frequently found in solid tumors and drives tumor-induced 
angiogenesis, blood flow disturbances, inflammatory cell 
infiltration, and tumor cell extravasation. Moreover, it can 
limit the efficacy of conventional therapies by impairing 
intravenous drug delivery. It is now accepted that not 
only excessive angiogenesis should be controlled but also 
vascular hyperpermeability [66]. High vascularization 
is associated with poor prognosis in NB [67] and 
combined treatments with anti-angiogenic agents showed 
promising benefits in preclinical models. Bevacizumab 
is a humanized monoclonal anti-VEGF antibody that 
neutralizes all isoforms of human VEGF. Dickson et al. 
reported that bevacizumab-mediated VEGF blockade 
caused alterations in tumor vessel physiology that 
permitted improved delivery and efficacy of chemotherapy 
[68, 69]. 
The use of miRNAs as therapeutic tools has 
recently entered in clinical development. One of the major 
challenges for miRNA-based therapies is to improve 
miRNA delivery, bioavailability and specific targeting to 
tumoral cells. In the field of oncology, the first molecule 
to enter in a phase I clinical trial was MIRX34 [70]. 
This compound is a double-stranded RNA mimic of the 
tumor suppressor microRNA, miR-34, encapsulated in a 
liposomal nanoparticle formulation. A limitation of this 
formulation is that when administered intravenously, its 
distribution is concentrated mainly in the liver, where it 
is very effective, but is metabolized and excreted quickly, 
limiting its therapeutic potential in less irrigated tissues 
[71]. In order to improve the specific targeting to tumoral 
cells, a recently-open phase I clinical trial sponsored by 
the University of Sidney, propose the use of miR-15/16 
mimics packaged in EDV™ nanocells targeted 
with Epidermal Growth Factor Receptor antibodies 
(TargomiRs) for the treatment of patients with recurrent 
malignant pleural mesothelioma and non-small cell lung 
cancer [72]. 
The downregulation of multiple DDR-related 
targets by a single miRNA, make miR-497 as a good 
therapeutic candidate not only as a monotherapy, but also 
in combination with current treatments. For example, 
miR-497 overexpression was reported to increase 
cisplatin-induced apoptosis in NB cell lines [29] or reduce 
the resistance to cisplatin in ovarian cancer using in vitro 
and in vivo models [58]. In line with the same evidence, 
high levels of miR-497 were found to be associated 
with better prognosis due to increased chemosensitivity 
in diffuse large B-cell lymphoma (DLBCL) patients. In 
this study, ectopic expression of miR-497 in DLBCL cell 
lines led to a reduction on cell viability after exposure 
to rituximab and different chemotherapeutics relevant in 
multi-agent lymphoma therapy [73].
In summary, our findings unveil miR-497 as a 
tumor-suppressor molecule in NB. The restoration of 
miR-497 may represent a novel and feasible therapeutic 
approach to treat high-risk NB by downregulating the 
expression of key proteins involved in DDR such as the 
cell cycle regulators WEE1 and CHEK1, cell growth and 





CHLA-90 cell line was obtained from the Children’s 
Oncology Group cell line repository. SK-N-BE(2), LA1-5s 
and SK-N-AS cell lines were purchased from ATCC. 
All cell lines obtained directly from the tissue banks 
were amplified and stored in liquid nitrogen. Upon 
resuscitation, cells were maintained in culture for no 
more than 2 months. All cell lines were cultured and 
maintained in Iscove’s Modified Dulbecco’s Medium 
(Life Technologies, Thermo Fisher Scientific), 
supplemented with 20% heat-inactivated FBS (South 
America Premium, Biowest), 1% Insulin-Transferrin-
Selenium G Supplement (Life Technologies, Thermo 
Fisher Scientific), 100 U/ml penicillin and 100 μg/mL 
streptomycin (Life Technologies, Thermo Fisher 
Scientific) and 5 µg/ml of Plasmocin Prophylactic 
(InvivoGen). All cultures were maintained at 37°C in a 
saturated atmosphere of 95% air and 5% CO2. 
Cell proliferation (crystal violet)
Liposomal transfection complexes without 
miRNA (MOCK) or with miRIDIAN microRNA Mimic 
oligonucleotides, Negative Control or Transfection 
Control with Dy547 (Dharmacon, GE Healthcare, 
25 nM per well) were generated with Lipofectamine 
2000 (Life technologies, Thermo Fisher Scientific, 
0.2 µL per well) in 96-well plates (6 replicates/condition) 
following the manufacturer’s recommendations. 
Cells were seeded at specific densities (SK-N-BE(2) 
10 × 103 cells/well, LA1-5s 5 × 103 cells/well, SK-N-AS 
8 × 103 cells/well, CHLA-90 16 × 103 cells/well) into wells 
containing liposomal complexes followed by overnight 
incubation in a humidified incubator at 37°C and 5% CO2. 
Media were changed 12–16 h later. At the indicated time 
points, cells were fixed with 1% glutaraldehyde (Sigma-
Aldrich) in PBS for 20 min and stored in PBS at 4°C. At 
the end of the experiment, cells were stained with 0.5% 
crystal violet (Sigma-Aldrich) for 20 min followed by 
extensive washing with diH2O. Crystals were dissolved 
with 15% acetic acid (Fisher Scientific) and optical 
density was read at 590 nm using an Epoch Microplate 
Spectrophotometer (Biotek).
Analysis of miRNA expression in human samples
Gene and miRNA expression data from 
neuroblastoma tumors was obtained from the Tumour 
Neuroblastoma Compendium (NRC) dataset. A total of 365 
neuroblastoma samples were obtained and analyzed from 
patients enrolled by Our Lady’s Hospital for Sick Children 
(Crumlin, Dublin, Ireland), the Children’s Oncology 
Group (Philadelphia, USA), the Ghent University 
Hospital (Ghent, Belgium), the Academic Medical Center 
(AMC; Amsterdam, Netherlands) and the University 
Children’s Hospital Essen (Essen, Germany). This 
work was approved by the Research Ethics Committee 
of each participating institute. Informed consent was 
obtained from the patients’ relatives. The investigators 
who deposited the data in the R2 repository agree to 
share the data for this work. Patient characteristics are 
listed in Supplementary Table 4. Tumors were profiled 
for 430 miRNAs plus 36 control small RNAs using 
individual Taqman PCR assays setup in 384-well format 
and mRNA gene expression profile was performed by 
Affymetrix GeneChip HG-U133plus2.0. The data set has 
been previously described in a number of publications 
[74–78]. Kaplan-Meier analysis was carried out using the 
scan function of the R2 data analysis tool at the University 
of Amsterdam (http://R2.amc.nl). The R2 Kaplan-Meier 
scanner for a single miRNA split the group in two and 
produced a graph containing 2 p-values. A raw p-value 
represented the log rank statistical significance. A 
Bonferroni corrected p-value indicated the significance in 
survival potential.
Cell death and caspase activity
CHLA-90, SK-N-AS, LA1-5s and SK-N-BE(2) 
cells were seeded at 105 × 103, 54 × 103, 35 × 103 and 
67 × 103 cells/24 well-plates, respectively. Cells were 
reverse transfected using Lipofectamine 2000 with 
miRIDIAN microRNA Mimic Negative Control and 
miRIDIAN microRNA Mimic miR-497 (25 nM) in 
triplicate and 6–8 h later media were changed. 96 h 
post-transfection, cell death was analyzed by Hoechst 
staining. Apoptosis quantification was made from 
4 representative images/well (n = 3 replicates per 
condition). Cells with uniformly stained chromatin were 
scored as healthy whereas those with fragmented and/or 
condensed chromatin were scored as apoptotic. 
For caspase-3/7 activity assays, SK-N-BE(2) and 
LA1-5s cells were seeded in 60-cm dishes and reverse 
transfected with 25 nM of Negative Control or miR-497 
oligonucleotides in triplicate. At 72 h post-transfection, 
cells were harvested and incubated for 15 minutes on 
ice with caspase-activity buffer (20 mM HEPES/NaOH 
pH 7.2, 10% sucrose, 150 mM NaCl, 5 mM EDTA, 1% 
Nonidet P-40, 0.1% CHAPS and 1x EDTA-free complete 
protease inhibitor cocktail (Roche)). Lysates were 
cleared by centrifugation at 13,000 × g for 5 min at 4°C, 
and supernatants were quantified by the Lowry method 
(Bio-Rad). Assays were performed in triplicate using 
15–25 µg of protein in the same lysis buffer supplemented 
with 10 mM DTT and 25 µM of the fluorogenic caspase-3 
substrate Ac-DEVD-AFC (Calbiochem). Plates were read 
in an Appliskan (Thermo Fisher Scientific) microplate 
reader using a 405 nm excitation filter and a 535 nm 
emission filter.
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Plasmids, lentivirus production and transduction
pTRIPZ was purchased from Open Biosystems 
(Dharmacon, GE Healthcare). To generate the 
miR-497 expression vector, a fragment of 184 
bp of pre-miR-497 was amplified by PCR (Fw: 
5′- GTTAACCTTCCCAGCACTGCTATGTG-3′ and Rv: 
5′-CTCGAGTGTCAACTTCTCCAGGATGG-3′) from 
genomic DNA and cloned directly into the pTRIPZ-empty 
vector using HpaI/XhoI restriction sites. Lentiviruses were 
propagated using previously described methods [79, 80]. 
SK-N-BE(2) and LA1-5s cells were seeded in 100 mm-
dishes and incubated overnight prior to infection. Medium 
was replaced with viral supernatant supplemented with 5 
µg/mL polybrene, and incubated for 24 h, followed by 
replacement with growth medium. pTRIPZ-Control or 
pTRIPZ-miR-497 stably-transduced SK-N-BE(2) and 
LA1-5s cells were selected with 1 µg/mL puromycin 
(Sigma-Aldrich) prior to use in experiments. 
Colony formation assay
pTRIPZ-Control or pTRIPZ-miR-497 stable SK-N-
BE(2) cells were seeded at 10,000 cells/well and pTRIPZ-
Control or pTRIPZ-miR-497 stable LA1-5s cells were 
seeded at 1,000 cells/well in 6-well plates in triplicates 
with 0.5 µg/mL of puromycin and with or without 
doxycycline (0.5–1 µg/mL). Medium was refreshed every 
3 days and cells were allowed to grow for 10–15 days. 
Then, cells were stained with crystal violet, photographed 
and scored
Cell proliferation assay (cell counting) 
pTRIPZ-Control or pTRIPZ-miR-497 stable SK-
N-BE(2) cells were seeded at 250,000 cells and pTRIPZ-
Control or pTRIPZ-miR-497 stable LA1-5s cells were 
seeded at 50,000 cells into 35 mm-dish with 0.5 µg/mL of 
puromycin and with or without doxycycline (0.5–1 µg/mL). 
Cells were counted and reseeded at days 3, 6 and 9 
(n = 3/condition).
Mouse xenograft 
SK-N-BE(2) cells transduced with pTRIPZ-
miR-497 (n = 20) were injected (5 × 106 cells/flank) into 
the right flank of 6–8-week-old female NMRI-nude mice 
(Janvier Labs, Le Genest-Saint-Isle, France). Cells were 
injected in 300 µl of PBS:Matrigel (Corning) (1:1). Once 
tumors were detected (day 4–5 post-injection), mice were 
randomized into two groups (n = 10/group). Doxycycline 
(1 mg/mL) was added (n = 10, miR-497 group) or not 
(n = 10, control) to the drinking water with 2% sucrose 
(Sigma-Aldrich). Tumor volume was measured every 
2–3 days for three weeks. At the end of the experiment, the 
primary tumors were excised and weighed. Tissues were 
fixed in 10% formalin, and paraffin-embedded. 
Immunohistochemistry
Vascularization was determined by a standard 
immunohistochemistry method in tissue sections using 
an anti-CD31 (PECAM1) antibody (ab28364, Abcam) 
and Envision anti-Rabbit HRP-conjugated secondary 
antibody complex (Dako). Hemorrhaging was determined 
by developing endogenous tissue peroxidase (mostly from 
red blood cells) using DAB precipitate deposition (Dako). 
Quantification of both vascularization and hemorrhaging 
was made from 3 representative images of 4 independent 
tumors per group, by determining area density (area 
positive for marker by total viable tumor area) using 
Image J software (NIH USA, open-source, public domain 
software).
Gene expression analysis by quantitative real-
time PCR 
Total RNA, including the small RNA fraction, 
was extracted using the miRNeasy Mini Kit (Qiagen). 
mRNAs were reverse transcribed (0.5–1 µg total RNA) 
using Taqman RT kit (Applied Biosystems, Thermo Fisher 
Scientific), and mature miRNA expression analysis was 
quantified using Taqman microRNA assays (Applied 
Biosystems, Thermo Fisher Scientific) following 
manufacturer’s recommendations. cDNA was quantified 
by standard RT-qPCR methodology using 2X Power 
SYBR Green Master Mix (Applied Biosystems, Thermo 
Fisher Scientific). Gene expression was normalized against 
the L27 housekeeping gene for mRNA, and U6 or RNU-44 
small RNA for miRNA analysis. The primer sequences are 
listed in Supplementary Table 5. The relative fold-change 
in expression was determined by the comparative 2(−ΔΔCT) 
method [81].
Western blot
Cell homogenates were obtained in RIPA buffer 
(Pierce, Thermo Scientific), supplemented with 
1 × EDTA-free complete protease inhibitor cocktail 
(Roche). Protein concentration was quantified by a 
modified Lowry assay (DC protein assay; Bio-Rad). 
30 µg of protein were resolved in NuPAGE 4-12% Bis-
Tris gels and transferred to iBlot Gel Transfer Stacks 
PVDF membranes (Life Technologies, Thermo Fisher 
Scientific). After blocking with Tris-buffered saline with 
Tween-20 containing 5% non-fat dry milk or 5% BSA 
for 1 h at room temperature, membranes were probed 
overnight at 4°C with the following antibodies: anti-PARP 
[1:2000, Cell Signaling #9542]; anti-CDC25A [1:1000, 
Santa Cruz #sc-7389]; anti-WEE1 [1:1000, Santa Cruz 
#sc-5285]; anti-CHK1 [1:2000, Santa Cruz #sc-8408]; 
anti-BCL2 [1:1000, Dako #M0887]; anti-AKT3 [1:1000, 
Upstate #05-780]; anti-VEGF [1:1000, Abcam #ab46154]; 
anti-Mouse IgG-Peroxidase antibody produced in rabbit 
(1:10.000, Sigma-Aldrich #A9044); anti-Rabbit IgG-
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Peroxidase antibody produced in goat (1:10.000, Sigma-
Aldrich #A0545) and anti-Actin HRP [1:40.000, Santa 
Cruz #sc-1616]. Membranes were developed with 
SuperSignal Dura detection kit (Pierce) or EZ-ECL 
Chemiluminescence detection kit (Biological Industries, 
Kibbutz Beit-Haemek, Israel).
Luciferase 3′UTR assays
psiCHECK™-2 vector was purchased from 
Promega. psiCHECK2-CHEK1 3′UTR construct 
was acquired from Addgene (plasmid 29478, [82]). 
pLightSwitch vector and pLightSwitch-AKT3 3′UTR 
were kindly provided by Doug Hanniford and Eva 
Hernando (NYU Langone Medical Center). psiCHECK2-
VEGFA 3′UTR vector was generated by amplifying a 
512bp fragment of the VEGFA 3′UTR by PCR (Fw: 
5′-CTCGAGGAACCAGATCTCTCACCAGGA-3′ and 
Rv: GCGGCCGCTCTCCTCCTCTTCCCTGTCA-3′) 
and cloned into the psiCHECK2™-2 vector using XhoI 
and NotI restriction sites. 
HEK293T cells were seeded in 96-well plates 
at 20,000 cells/well in 100 µL/well of complete 
media without antibiotic. Cells were co-transfected 
16–24 h later using Lipofectamine 2000 with 50 ng 
of psiCHECK2-CHEK1 3′UTR, pLightSwitch-AKT3 
3′UTR or psiCHECK2-VEGFA 3′UTR vector and 25 nM 
of miR-497 mimic or negative control. Liposomal 
complexes containing 3′UTR and liposomal Mimic 
miRNAs were prepared separately in 50 µL volume and 
then added consecutively to 96-well seeded HEK293T 
cells. Cells were incubated at 37°C and 5% CO2 for 
20–24 h. Luciferase assay was performed using the 
Dual-Glo® Luciferase Assay System (Promega) for 
psiCHECK2 constructs and LightSwitch Luciferase Assay 
Reagent™ (SwitchGear Genomics) for pLightSwitch 
constructs, respectively, following the manufacturer’s 
recommendations. Luminescence was measured in 
an Appliskan (Thermo Fisher Scientific) microplate 
reader. Renilla luciferase activity was normalized to 
corresponding firefly luciferase activity (pisCHECK2 
constructs) and plotted as a percentage of the control.
Statistical analysis 
Unless otherwise indicated, mean values ± SEM 
are representative of one out of three independent 
experiments. Statistical significance was determined by 
two-tailed unpaired Student’s t-test (GraphPad Prism 
Software). * means p < 0.05, ** means p < 0.01 and *** 
means p < 0.001.
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